{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:48:30Z","timestamp":1793382510200,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.disamonth.2024.101753","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:43:47Z","timestamp":1718970227000},"page":"101753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies"],"prefix":"10.1016","volume":"70","author":[{"given":"Frederick","family":"DeRosier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Hibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderbir","family":"Padda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2024.101753_bib0001","first-page":"61","article-title":"The differential diagnosis and treatment of atypical parkinsonism","volume":"113","author":"Levin","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.disamonth.2024.101753_bib0002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0003","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.26455","article-title":"Long-duration progressive supranuclear palsy: clinical course and pathological underpinnings","volume":"92","author":"Lukic","year":"2022","journal-title":"Ann Neurol"},{"issue":"49","key":"10.1016\/j.disamonth.2024.101753_optBjCZNbQKJu","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice","volume":"36","author":"Liu","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.571800","article-title":"Clinical features of patients with progressive supranuclear palsy in an US insurance claims database","volume":"12","author":"Viscidi","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0006","series-title":"Progressive Supranuclear Palsy Fact Sheet","year":"2015"},{"key":"10.1016\/j.disamonth.2024.101753_bib0007","first-page":"1117","article-title":"Diagnostic approach to atypical parkinsonian syndromes","volume":"22","author":"McFarland","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.disamonth.2024.101753_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-444-64012-3.00009-5","article-title":"Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration","volume":"165","author":"Fabbrini","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0009","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.13396","article-title":"Depression and apathy across different variants of progressive supranuclear palsy","volume":"9","author":"Bower","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.disamonth.2024.101753_bib0010","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mdc3.13435","article-title":"Do patients with progressive supranuclear palsy have episodic memory impairment? a systematic review","volume":"9","author":"Macedo","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.disamonth.2024.101753_bib0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0012","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.27034","article-title":"Which ante mortem clinical features predict progressive supranuclear palsy pathology?","volume":"32","author":"Respondek","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0013","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/mds.24968","article-title":"Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy","volume":"27","author":"Massey","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0014","doi-asserted-by":"crossref","first-page":"145","DOI":"10.33160\/yam.2018.09.001","article-title":"Role of neuroimaging on differentiation of parkinson's disease and its related diseases","volume":"61","author":"Ogawa","year":"2018","journal-title":"Yonago Acta Med"},{"key":"10.1016\/j.disamonth.2024.101753_bib0015","series-title":"Progressive Supranuclear Palsy","author":"Agarwal","year":"2021"},{"key":"10.1016\/j.disamonth.2024.101753_bib0016","series-title":"UpToDate","article-title":"Progressive supranuclear palsy (PSP): clinical features and diagnosis","author":"Factor","year":"2021"},{"key":"10.1016\/j.disamonth.2024.101753_bib0017","doi-asserted-by":"crossref","unstructured":"Jones J., Gaillard F. Progressive supranuclear palsy. Reference article: Radiopaedia.org; 2008.","DOI":"10.53347\/rID-1924"},{"key":"10.1016\/j.disamonth.2024.101753_bib0018","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00401-022-02483-8","article-title":"Single-nucleus chromatin accessibility profiling highlights distinct astrocyte signatures in progressive supranuclear palsy and corticobasal degeneration","volume":"144","author":"Briel","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0019","doi-asserted-by":"crossref","first-page":"122","DOI":"10.14802\/jmd.15033","article-title":"Genetics of progressive supranuclear palsy","volume":"8","author":"Im","year":"2015","journal-title":"J Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0021","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/brain\/123.5.880","article-title":"Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations","volume":"123","author":"Stanford","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.disamonth.2024.101753_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2010.07.010","article-title":"Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice","volume":"40","author":"Melrose","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.disamonth.2024.101753_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.45.1.127","article-title":"Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA","volume":"45","author":"Levy","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2024.101753_bib0024","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.410320516","article-title":"Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study","volume":"32","author":"Pascual","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","article-title":"Cellular and pathological heterogeneity of primary tauopathies","volume":"16","author":"Chung","year":"2021","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.disamonth.2024.101753_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40478-019-0708-4","article-title":"How to demix Alzheimer-type and PSP-type tau lesions out of their mixture -hybrid approach to dissect comorbidity","volume":"7","author":"Ebashi","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.disamonth.2024.101753_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00688244","article-title":"Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer's disease","volume":"77","author":"Probst","year":"1988","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JPD-202302","article-title":"Genetics of Progressive Supranuclear Palsy: a Review","volume":"11","author":"Wen","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.disamonth.2024.101753_bib0029","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive supranuclear palsy: advances in diagnosis and management","volume":"73","author":"Coughlin","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamaneurol.2019.0250","article-title":"Association of MAPT subhaplotypes with risk of progressive supranuclear palsy and severity of tau pathology","volume":"76","author":"Heckman","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0031","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/mds.27196","article-title":"Genetic influences on cognition in progressive supranuclear palsy","volume":"32","author":"Gerstenecker","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0032","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.27702","article-title":"Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy","volume":"34","author":"Chen","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(20)30394-X","article-title":"Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study","volume":"20","author":"Jabbari","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0034","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ng.859","article-title":"Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy","volume":"43","author":"Hoglinger","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.disamonth.2024.101753_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JPD-202302","article-title":"Genetics of Progressive Supranuclear Palsy: a Review","volume":"11","author":"Wen","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.disamonth.2024.101753_bib103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-018-0267-3","article-title":"Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci","volume":"13","author":"Sanchez-Contreras","year":"2018","journal-title":"Mol Neurodegeneration"},{"key":"10.1016\/j.disamonth.2024.101753_bib0036","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/brain\/awaa428","article-title":"Two heterozygous progranulin mutations in progressive supranuclear palsy","volume":"144","author":"Wanlin","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.disamonth.2024.101753_bib0037","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.parkreldis.2016.10.013","article-title":"Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy","volume":"34","author":"Wiblin","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.parkreldis.2019.07.010","article-title":"Progression of two progressive supranuclear palsy phenotypes with comparable initial disability","volume":"66","author":"Shoeibi","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0039","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-019-09324-x","article-title":"Motor, cognitive and behavioral differences in MDS PSP phenotypes","volume":"266","author":"Picillo","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0040","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1007\/s00415-021-10511-y","article-title":"Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes","volume":"268","author":"Horta-Barba","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0041","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ane.13372","article-title":"Abnormal structural connectivity in progressive supranuclear palsy\u2014Richardson syndrome","volume":"143","author":"Prasad","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.disamonth.2024.101753_bib0042","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/jnnp-2019-321354","article-title":"Midbrain MRI assessments in progressive supranuclear palsy subtypes","volume":"91","author":"Picillo","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101753_bib0043","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2021.01.015","article-title":"Association of PSP phenotypes with survival: a brain-bank study","volume":"84","author":"Guasp","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 1","key":"10.1016\/j.disamonth.2024.101753_bib0044","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/brain\/120.1.65","article-title":"Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study","volume":"120","author":"Litvan","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.disamonth.2024.101753_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00508-016-1096-4","article-title":"Gait disorders in adults and the elderly : a clinical guide","volume":"129","author":"Pirker","year":"2017","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.disamonth.2024.101753_bib0046","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0042-6989(00)00046-8","article-title":"Visual-vestibular interaction in progressive supranuclear palsy","volume":"40","author":"Das","year":"2000","journal-title":"Vision Res"},{"key":"10.1016\/j.disamonth.2024.101753_bib0047","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1212\/01.wnl.0000304134.33380.1e","article-title":"Why do patients with PSP fall? Evidence for abnormal otolith responses","volume":"70","author":"Liao","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2024.101753_bib0048","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fneur.2010.00147","article-title":"The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis","volume":"1","author":"Chen","year":"2010","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0049","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s00415-009-0027-y","article-title":"Differential diagnostic value of eye movement recording in PSP-parkinsonism, Richardson's syndrome, and idiopathic Parkinson's disease","volume":"255","author":"Pinkhardt","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0050","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/mdc3.13001","article-title":"Apraxia of eyelid opening improved by pallidal stimulation in progressive supranuclear palsy","volume":"7","author":"Orcutt","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.disamonth.2024.101753_bib0051","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2019.07.030","article-title":"Dystonia in atypical parkinsonian disorders","volume":"66","author":"Marsili","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0052","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/awz344","article-title":"Evolving concepts on bradykinesia","volume":"143","author":"Bologna","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.disamonth.2024.101753_bib0053","doi-asserted-by":"crossref","DOI":"10.17659\/01.2015.0097","article-title":"Parkinson's disease and early stages of progressive supranuclear palsy: a neurological mimicry","author":"George","year":"2015","journal-title":"Journal of Case Reports"},{"key":"10.1016\/j.disamonth.2024.101753_bib0054","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00415-015-7990-2","article-title":"Progressive supranuclear palsy: progression and survival","volume":"263","author":"Arena","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0055","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.22794","article-title":"A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy","volume":"25","author":"Schrag","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0056","first-page":"504","article-title":"Parkinson's disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.disamonth.2024.101753_bib0057","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/nmt-2016-0027","article-title":"Managing cognition in progressive supranuclear palsy","volume":"6","author":"Rittman","year":"2016","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.disamonth.2024.101753_bib0058","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/mds.27619","article-title":"Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy","volume":"34","author":"Ali","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0059","series-title":"UpToDate","article-title":"Initial pharmacologic treatment of Parkinson disease","author":"Spindler","year":"2021"},{"key":"10.1016\/j.disamonth.2024.101753_bib0060","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/acn3.51065","article-title":"MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome","volume":"7","author":"Frank","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0061","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2019.10.012","article-title":"Are the International parkinson disease and movement disorder society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?","volume":"69","author":"Shoeibi","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0062","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12883-020-01692-6","article-title":"Midbrain\/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy","volume":"20","author":"Cui","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0063","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0000000000001163","article-title":"Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment","volume":"36","author":"Veilleux Carpentier","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0064","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/mds.28364","article-title":"A New MRI measure to early differentiate progressive supranuclear palsy from de novo parkinson's disease in clinical practice: an international study","volume":"36","author":"Quattrone","year":"2021","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.9588","article-title":"Diagnostic accuracy of magnetic resonance imaging measures of brain atrophy across the spectrum of progressive supranuclear palsy and corticobasal degeneration","volume":"5","author":"Ill\u00e1n-Gala","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.disamonth.2024.101753_bib0066","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/diagnostics12010012","article-title":"Diagnostic performance of the magnetic resonance parkinsonism index in differentiating progressive supranuclear palsy from parkinson's disease: an updated systematic review and meta-analysis","author":"Kim","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.disamonth.2024.101753_bib0067","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3906\/sag-2008-253","article-title":"Dopamine transporter SPECT imaging in Parkinson's disease and parkinsonian disorders","volume":"51","author":"Akdemir","year":"2021","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0068","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"Bajaj","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.disamonth.2024.101753_bib0069","series-title":"UpToDate","article-title":"Progressive supranuclear palsy (PSP): management and prognosis","author":"Factor","year":"2021"},{"key":"10.1016\/j.disamonth.2024.101753_bib0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1353-8020(97)00022-9","article-title":"Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy","volume":"3","author":"Rajrut","year":"1997","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.606925","article-title":"Associations between amantadine usage, gait, and cognition in PSP: A","volume":"11","author":"Dale","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0072","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jocn.2009.05.038","article-title":"The use of zolpidem in the treatment of progressive supranuclear palsy","volume":"17","author":"Cotter","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0073","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1532-5415.1996.tb02940.x","article-title":"Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects","volume":"44","author":"Engel","year":"1996","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.disamonth.2024.101753_bib0074","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0269215519877235","article-title":"Exercise and physical activity for people with progressive supranuclear palsy: a systematic review","volume":"34","author":"Slade","year":"2020","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.disamonth.2024.101753_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170927","article-title":"Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments","volume":"12","author":"Clerici","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.disamonth.2024.101753_bib0076","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mds.870090605","article-title":"Apraxia of lid opening,\" a focal eyelid dystonia: clinical study of 32 patients","volume":"9","author":"Krack","year":"1994","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101753_bib0077","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20546","article-title":"Toward future therapies in progressive supranuclear palsy","volume":"20","author":"Burn","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135823","article-title":"Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study","volume":"10","author":"Tomita","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.disamonth.2024.101753_bib0079","series-title":"UpToDate","article-title":"Clinical manifestations of Parkinson disease","author":"Chou","year":"2021"},{"key":"10.1016\/j.disamonth.2024.101753_bib0080","series-title":"UpToDate","article-title":"Diagnosis and differential diagnosis of Parkinson disease","author":"Chou","year":"2021"},{"key":"10.1016\/j.disamonth.2024.101753_bib0081","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00314665","article-title":"Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage","volume":"237","author":"Iwasaki","year":"1990","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0082","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jocn.2020.06.008","article-title":"Clinical, MRI and 18F-FDG-PET\/CT analysis of progressive supranuclear palsy","volume":"80","author":"Zhao","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0083","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fnagi.2020.00126","article-title":"Increased noradrenaline as an additional cerebrospinal fluid biomarker in PSP-Like parkinsonism","volume":"12","author":"Cerroni","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0084","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0086","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.disamonth.2024.101753_bib0087","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.25815","article-title":"Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial","volume":"29","author":"H\u00f6glinger","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2024.101753_bib0088","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2174\/1567205015666180119104036","article-title":"Tolfenamic acid: a modifier of the tau protein and its role in cognition and tauopathy","volume":"15","author":"Chang","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.disamonth.2024.101753_bib0089","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschemneuro.2c00057","article-title":"O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and \u03b1-synuclein proteinopathies","volume":"13","author":"Permanne","year":"2022","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0090","doi-asserted-by":"crossref","first-page":"16806","DOI":"10.1038\/s41598-021-94708-1","article-title":"AZP2006, a new promising treatment for Alzheimer's and related diseases","volume":"11","author":"Callizot","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.disamonth.2024.101753_bib0091","unstructured":"NCT04008355. A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP. https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.disamonth.2024.101753_bib0093","first-page":"19","article-title":"An overview on the clinical development of tau-based therapeutics","author":"Medina","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2024.101753_bib0094","first-page":"10","article-title":"RT001 in progressive supranuclear palsy-clinical and in-vitro observations","author":"Angelova","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.disamonth.2024.101753_bib0095","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.disamonth.2024.101753_bib0096","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00401-021-02318-y","article-title":"Tau immunotherapy is associated with glial responses in FTLD-tau","volume":"142","author":"Kim","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0097","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2024.101753_bib0098","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.trci.2018.10.007","article-title":"A randomized, single ascending dose study of intravenous BIIB092 in healthy participants","volume":"4","author":"Qureshi","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.disamonth.2024.101753_bib0099","unstructured":"NCT04185415. A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP). https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.disamonth.2024.101753_bib0100","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.disamonth.2024.101753_bib0101","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathol"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T07:26:54Z","timestamp":1723274814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502924000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0011502924000798"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101753","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101753"}}